Drugs / Recombinant human TNF-α
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01490047 | Jan 2013 → ? | cancer, lymphoma | Ludwig Institute for Cancer Research | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human TNF-α | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01490047 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus.” NCT01490047 ↗ |
| Route | Intravenous | “given as a single dose intravenously” NCT01490047 ↗ |